Pretargeting for imaging and therapy in oncological nuclear medicine - Archive ouverte HAL Access content directly
Journal Articles European Association of Nuclear Medicine, issuing body - EJNMMI radiopharmacy and chemistry Year : 2017

Pretargeting for imaging and therapy in oncological nuclear medicine

(1, 2) , (1, 2) , (3, 2) , (1, 2) , (3, 2) , (4, 5)
1
2
3
4
5

Abstract

Background: Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles. Results: We have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibodyoligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting. Conclusions: While pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives.
Fichier principal
Vignette du fichier
41181_2017_Article_26.pdf (818.88 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

inserm-01819175 , version 1 (20-06-2018)

Identifiers

Cite

Clément Bailly, Caroline M Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, et al.. Pretargeting for imaging and therapy in oncological nuclear medicine. European Association of Nuclear Medicine, issuing body - EJNMMI radiopharmacy and chemistry, 2017, 2 (1), pp.6. ⟨10.1186/s41181-017-0026-8⟩. ⟨inserm-01819175⟩
88 View
74 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More